Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey

Abstract

Background

The International Society of Oncology Pharmacy Practitioners (ISOPP) Biosimilar Task Force was charged to develop educational resources to address the learning needs related to biosimilars use of oncology pharmacy practitioners. To facilitate the process, the task force conducted a survey in order to identify unmet education needs as well as barriers for obtaining biosimilar education among oncology pharmacy practitioners.

Methods

A cross sectional survey was conducted between 10 December 2018 and 18 February 2019. Members of International Society of Oncology Pharmacy Practitioners and national oncology pharmacy groups were invited to complete the survey. The survey contained 22 items and consisted of four sections. Descriptive statistics were utilized to analyze the survey results.

Results

A total of 363 International Society of Oncology Pharmacy Practitioners members were surveyed, with 75 members providing a response (response rate = 21%). In addition, 11 non-International Society of Oncology Pharmacy Practitioners members also participated in the survey, bringing the total to 86 respondents. The top three areas in which respondents reported learning needs included evaluating comparative efficacy of a biosimilar to an originator’s product (74.4%), managing the switchover to a biosimilar from the original product (74.4%), and understanding medication safety issues in relation to biosimilars use (73.3%). The most common challenges faced in obtaining education on biosimilars included limited financial support for education on biosimilar products (38.4%), heavy workload (31.4%), and inadequate educational resources (27.9%).

Conclusion

This survey has identified numerous biosimilar learning needs as well as challenges faced in obtaining biosimilars education among oncology pharmacy practitioners. Educational activities should be created to address these learning needs, and innovative strategies should be considered to overcome practitioner’s barriers in obtaining biosimilars education.

Keywords

Get full access to this article

View all access options for this article.

References

Wolff-Holz

Garcia Burgos

Giuliani

, et al. Preparing for the incoming wave of biosimilars in oncology. ESMO Open 2018; 3: e000420.

Giuliani

Tabernero

Cardoso

, et al. Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. ESMO Open 2019; 4: e000460.

Pasina

Casadei

Nobili

A survey among hospital specialists and pharmacists about biosimilars.

Eur J Intern Med 2016; 35: e31–e33.

Leonard

Wascovich

Oskouei

, et al. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm 2019; 25: 102–112.

American Society of Health-System Pharmacists. A health-system pharmacist’s guide to biosimilars: regulatory, scientific, and practical considerations, https://ashpadvantagemedia.com/downloads/biosimcentral_guidelines.pdf (accessed 27 October 2019).

Cook

McGrath

Dixon

, et al. Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing. Ther Adv Med Oncol 2019; 11: 1758835918818335.

Weise

Bielsky

De Smet

, et al. Biosimilars: what clinicians should know. Blood 2012; 120: 5111–5117.

Beck

Michel

Rybarczyk-Vigouret

, et al. Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: results of a French web-based survey. MAbs 2017; 9: 383–390.

Trotta

Mayer

Mecozzi

, et al. Impact of guidance on the prescription patterns of G-CSFs for the prevention of febrile neutropenia following anticancer chemotherapy: a population-based utilization study in the Lazio region. BioDrugs 2017; 31: 117–124.